click enter text
smaller tweak balanc
report first-tim guidanc provid updat
upcom pipelin catalyst tuesday morn
far back year ago given oper margin guidanc
chang new line item specif overal
guidanc came expect
one better growth outlook versu group explain
second-highest price-to-earnings multipl group good compani overal
one appear fairli valu us given outlook
forecast chang modestli next year price target
rise virtu accord higher target price-to-earnings multipl
ep rate remain peer-perform
inform us/eu stock cover see global
 dec issu monthli controversi report
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
overal impress tuesday market open report first-tim guidanc provid
updat upcom pipelin catalyst far back year ago given oper margin guidanc
guidanc element remain unchang new line item specif overal
guidanc came expect mani talk point ep reiter
last recent lli share price sideway stock paus follow nice run
earli investor mainli concern competit dynam could impact trulic
diabet portfolio broadli taltz immunology/inflamm two compani biggest futur growth
driver much new reveal front guidanc call rel said
one better growth outlook versu group explain second-highest price-to-earnings multipl group
good compani overal one appear fairli valu us given outlook sourc upsid option
cogniz perhap biggest would progress compani alzheim diseas portfolio
someth taken new life follow recent disclosur once-dead aducanumab
forecast chang modestli price target rise virtu accord higher target price-to-earnings multipl
ep rate remain peer-perform inform us/eu
stock cover see dec issu monthli controversi report
revenu estim rang ep rang
bigger chang out-year estim primarili reflect advanc earli stage factor
close current calendar year
ep compound-annual-growth-rate ep compound-annual-growth-rate increas repres averag
pt price target increas repres price-to-earnings multipl ep
one driver target multipl expans captur option within alzheim diseas
portfolio investor new willing pay
exhibit summar lli new financi guidanc vs estim
page
 elementwr bgross marginapprox bother meffect tax rateapprox oper incom approx guidanc
exhibit captur chang forecast
exhibit chang wr model
back first gave guidanc cusp solanezumab expedit data
commit annual minimum revenu growth least subsequ rais w/o elanco
oper margin without elanco drive innov nme increas
dividend annual
innov launch pain immunolog acquir precis oncolog platform increas
 effici reduc time first dose launch year navig key pipelin
failur like lartruvo evacetrapib solanezumab
track drive greater revenu compound-annual-growth-rate bp oper margin expans launch nme
ye annual dividend increas deploy capit extern
transact go sharehold dividend share repurchas
page
gener high singl digit growth driven new product portfolio volum growth
anticip number poc readout across key ta replenish pipelin look extern
innovation/bolt-on acquisit evergreen portfolio expect continu return cash sharehold
repurchas maintain ig debt rate
posit factor guidanc uptak key growth product revenu trulic class
growth market share increas addit rewind indic drive volum growth off-set
modest price headwind build taltz profil head-to-head trial vs humira tremfya
pso pleas emgal uptak lead nbrx driven access eas use continu
growth primari care set verzenio posit os data monarch meaning drive
util jardianc ad share point acceler class new therapi start
potenti indic chf ckd new facet growth stori drive uptak product ou
includ olumi second largest volum driver europ monarch verzenio
stop interim efficaci drive china growth sunset headwind us ciali loe
lartruvo withdraw continu realiz effici exist commerci footprint
neg expect forteo gener global price declin expect mid-singl digit
low-single-digit us mid-single-digit japan due price cut quarter mid-single-digit
declin eu alimta nrdl list drive double-digit-declin china revis
boehring allianc jardianc sale china antibiot healthcar reform troop cliff increas
pharma contribut patient take longer reach catastroph assum reform yet
impact less view unlik pass senat mention support
senat financ committe bill oppos inflat cap support rebat reform oie doesnt
expect gain invest tax benefit repeat
see exhibit expect end toward top end non-gaap ep rang note oie
impact sale antibiot busi china
guidanc see exhibit revenu expect grow high-single-digit minim neg
fx impact compound-annual-growth-rate midpoint gross margin expect improv yoy due
manufactur improv sg increas modestli new launch off-set product
improv increas mid-singl digit due higher ph activ tirzepatid mirikizumab
selpercatinib togeth get oper margin oie hit non-rep gain
invest volatil tax rate increas bp net discret benefit
expect recur ep growth mid-teen rang margin expans mute increas
throughout year
outlook expect key growth driver continu ramp us ou
augment new launch sale expos alimta tradjenta continu
drive volum growth off-set global price headwind flag alzheim diseasea upsid estim
growth underpin asset like kra continu extern innov complement key ta
next five year natur extens last five year
china growth alreadi first nine month launch includ trulic olumi
taltz also success launch partner product tyvyt innov elun hutchinson
china meditech recent ad nrdl
highli select non-coval btk bruin poc data present signific
efficaci seen cll mcl regardless prior therapi acquir resist mutat statu
page
respons deepen time onset resolut lymphocytosi consist
therapi believ signal extend cancer safeti well understood
dlt reach bruin continu enrol present data
dose patient ph trial kra inhibitor lung solid tumor
competit field view combo approach key drive robust outcom patient
confid combo strategi on-going trial
serd field struggl due toxic shown antitumor efficaci look forward assess
serd monotherapi combo regimen abemaciclib
event ph initi tirzepatid head-to-head trulic cvot selpercatinib nsclc
mtc data empire-reduc jardianc first readout surpass program tirzepatid
data solanezumab dominantli inherit alzheim taltz approv non-radiographic-axspa
selpercatinib decis potenti ou launch program
 yoy increas what justif small increas
increas high watermark due larg number ph initi theyr
increas flow pipelin highest number ph start number ph program
dont read level invest continu see growth think theyll exceed
period
 event show anyth statu product show
cypress studi wrap year share data last patient enrol june
need month follow-up dataset continu explor differ biomark opportun
believ pegilodecakin need biomarker-driven approach renal cancer studi start well
 driver gross margin mix benefit effici discret event like plant shutdown
pleas opportun see realli driven manufactur effici includ
unit cost reduct technolog improv next five year dont think theyll see signific
 updat time expect dian studi read read earli
 comment loxo decis stay opportun reason abil put
import new cancer med across finish line singl motiv part journey
independ see wider scale due larger team
 frame factor forteo basaglar pressur revenu ep rang
contempl competit product econom import forteo somewhat
meaning impact us revenu less impact competit basaglar
page
 price low singl digit eros us new normal one increment impact
troop cliff continu plan continu price eros
increment impact low singl declin key ta normal
 dynam taltz derm rheum dermatolog competit theyr encourag
five year durabl superior vs tremfya encourag rheum especi
superior trial vs humira achiev label pariti vs cosentyx updat notic impact
past week derm patient still receiv humira rheum patient see
signific opportun
 think posit need see dlt registr trial design
first start hypothesi would work patient acquir mutat primarili
cll clearli demonstr efficaci set need continu follow inform durabl could
work salvag set potenti earlier line therapi evalu cours
whether broad develop plan appropri therapeut index posit well combo
regimen dont necessarili need see dlt move program
 trulic high dose rewind much factor base fundament
strong market growth high trulic outpac guidanc base market
fundament high dose rewind increment
 defin peer set look project brand pharmaceut growth
 assumpt would upsid encourag strong data treatment-nav
includ nda file nsclc thyroid dont think theyll get approv set
single-arm studi btd notifi earli whether prioriti
 could bruin registr r/r set could mrd use acceler approv earlier
line earli say whether bruin could enough approv regulatori question
mind mrd yet valid endpoint regul incorpor concept
clinic program design base case reli convent endpoint
 think sfc propos could increas part access trulic volum
part anyth reduc pocket cost get rebat pass through good patient
would provid volum benefit trulic benefit across diabet portfolio
coverag across commerci medicar
 dian-tu speak plaqu clearanc dose also would cdr-sb reduct
look like dian-tu endpoint power learn interim ye
use dose cant speak impact plaqu sola effect plaqu reduc
antibodi target solubl form cant give comparison cdr-sb new endpoint dian-
tu power small number patient patient driven genet mutat could
homogen effect
page
 verzenio what time monarch- readout final readout wont talk
ph interim readout note encourag result cant share
specif around sap either
 updat time design effect plaque-low antibodi help
address solubl vs oligomer ab debat get final data decemb expect full data
earli scrub data
 expect sequenti earn progress base thing sunset
youll see less benefit alreadi note margin expans weight
probabl lower
 durabl kra product potenti earlier line treatment theyv seen
durabl nsclc look shorter target therapi question whether extend
combo regimen excit hand combo target lli combo strategi make
strateg relev genom profil happen set see target oncolog
product use
 use combo regiment potenti earlier line treatment wont disclos
combin right think ration combo regimen key answer whether move
earlier line therapi
 want refocu investor attent alzheim diseas asset view import
option lilli import bet amyloid beta test hypothesi continu invest
behind diseas anti-tau symptomat asset ph read
 updat trulic jardianc access expect
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement incom loss cont op dilut share growth outstand
page
product revenu emgal galcanezumab anti-cgrp growth share tradjenta basaglar biosimilar share jardianc trulic women endocrinolog growth diabet alimta cyramza gastric lartruvo olaratumab verzenio abemaciclib erbitux total taltz ixekizumab olumi baricitinib jak total total earli stage factor- total
exhibit wr eli lilli balanc sheet cash flow statement
page
summari statement incom reconcil incom tax cash provid oper tax chang oper asset defer compens impair net in-process technolog net cash provid sale in-process product paid acq/loan cash provid use invest stock capit chang short term issuanc long term repay long-term cash provid use financ exchang rate cash increas decreas end balanc sheet cash equival short term properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold liabil sharehold
